Alzheimer’s setback prompts rethink of Lilly, Biogen stock outlooks

Posted on November 26th, 2016 by aaliyahmcadam70

By Lewis Krauskopf NEW YORK, Nov 23 (Reuters) – Eli Lilly & Co’s massive setback for its experimental Alzheimer’s disease treatment on Wednesday sent investors scrambling to re-evaluate shares of the U.S. drugmaker and those of companies making competing therapies, including biotech stalwart Biogen Inc . Lilly shares tumbled 10.5 percent, and fell to their […]

Read More